Expert Interview
Q4 #3: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Ticker(s): BIIB, ESAIYInstitution: Heritage Medical Associates
- Extensive experience in Headache and Neuromuscular & Movement Disorders.
- Currently manages 80 patients with AD agitation
- Board certified in both Neurology and Vascular Neurology and is a clinical assistant professor of neurology at Vanderbilt.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
